Atrial Fibrillation Management

Introduction to Management Objectives

The European Society of Cardiology recommends prevention of thromboembolism, symptom relief, optimal management of concomitant cardiovascular diseases, rate control, and correction of rhythm disturbance as key objectives in managing patients with atrial fibrillation 3

The European Heart Society recommends direct oral anticoagulants (DOACs) in preference to vitamin K antagonists (VKAs) for eligible patients with non-valvular atrial fibrillation 4
Anticoagulation decision should be based on stroke risk assessment using validated tools like CHA₂DS₂-VA score, with patients having a score ≥2 receiving anticoagulation 5
Patients with a CHA₂DS₂-VA score of 1 should be considered for anticoagulation, and bleeding risk factors should be managed but not used to decide against starting anticoagulation 5

The American College of Cardiology recommends beta-blockers, diltiazem, verapamil, or digoxin as first-choice drugs for patients with atrial fibrillation and left ventricular ejection fraction (LVEF) >40% 4
Beta-blockers and non-dihydropyridine calcium channel blockers are recommended for their efficacy in controlling heart rate both at rest and during exercise 1, 2
Digoxin should only be used as a second-line agent as it is only effective for rate control at rest 1, 2

The European Heart Society recommends considering rhythm control in symptomatic patients with persistent atrial fibrillation as part of a comprehensive approach 4
Early rhythm control (within 12 months of diagnosis) should be considered in selected patients with atrial fibrillation at risk of thromboembolic events 4
Cardioversion options include both electrical (direct-current) and pharmacological conversion, and antiarrhythmic drugs for rhythm maintenance should be selected based on patient-specific risk factors for side effects 1, 2
Catheter ablation should be considered as a second-line option if antiarrhythmic drugs fail, or as first-line in patients with paroxysmal atrial fibrillation 5

Transesophageal echocardiography (TEE) with short-term anticoagulation followed by early cardioversion is an appropriate strategy for patients undergoing cardioversion, and anticoagulation should be continued in patients at elevated thromboembolic risk after ablation 1, 2, 4
Concomitant cardiovascular conditions should be optimally managed as they can contribute to atrial fibrillation development and recurrence, and modifiable risk factors such as hypertension, heart failure, diabetes mellitus, obesity, obstructive sleep apnea, physical inactivity, and high alcohol intake should be addressed 3, 5, 6

Multiple clinical trials have shown no significant difference in mortality between rate and rhythm control strategies, emphasizing the importance of continued anticoagulation regardless of the chosen strategy 3, 7